Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Change in Accured Expenses (2020 - 2024)

Immuneering has reported Change in Accured Expenses over the past 5 years, most recently at -$718.0 for Q4 2024.

  • Quarterly results put Change in Accured Expenses at -$718.0 for Q4 2024, down 100.11% from a year ago — trailing twelve months through Dec 2024 was -$200831.0 (down 127.82% YoY), and the annual figure for FY2025 was $57848.0, up 128.8%.
  • Change in Accured Expenses for Q4 2024 was -$718.0 at Immuneering, down from $1.2 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for IMRX hit a ceiling of $2.0 million in Q2 2021 and a floor of -$2.2 million in Q1 2022.
  • Median Change in Accured Expenses over the past 5 years was $69982.0 (2021), compared with a mean of $226035.6.
  • Biggest five-year swings in Change in Accured Expenses: soared 2770.14% in 2023 and later crashed 3712.3% in 2024.
  • Immuneering's Change in Accured Expenses stood at -$257046.0 in 2020, then surged by 314.39% to $551080.0 in 2021, then tumbled by 104.49% to -$24766.0 in 2022, then soared by 2770.14% to $661288.0 in 2023, then plummeted by 100.11% to -$718.0 in 2024.
  • The last three reported values for Change in Accured Expenses were -$718.0 (Q4 2024), $1.2 million (Q3 2024), and -$1.2 million (Q2 2024) per Business Quant data.